SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
LINDSEY ROEKER (NEW YORK)
VENETOCLAX AND PI3KI REAL WORLD EVIDENCE
This presentation focuses on data that are uniquely made possible through real world
evidence including description of efficacy and safety in non-trial populations and attempts to
answer questions that are not going to be answered with planned clinical trials. Data
regarding efficacy and safety outcomes for patients treated with venetoclax and PI3K
inhibitors are reviewed in detail, as well as real world studies on novel agent sequencing.
For further reading:
Mato AR et al. Haematologica 2018;103(9):1511-1517
Eyre TA et al. BJH 2019;185:656-669
Eyre TA, Roeker LE et al. BJH 2019;188:918-923
Anderson MA et al. Blood 2017;129(25):3362-3370
Mato AR et al. Blood Adv 2019;3(10):1568-1573
Roeker LE et al. Clin Cancer Res 2019;25(14):4264-4270
Bird ST et al. JAMA Onc 2020;6(2):248-254
Pula B et al. Anticancer Res 2018;38:3025-3030
Michallet AS et al. Blood 2018;132(Supp 1):2302
Fernando F et al. Blood 2017;130(Supp 1):1733
Knauf W et al. EHA Library 2018;215970;PB1874
Hoechstetter M et al. Blood 2018;132(Supp 1):4428
Bange E et al. Blood 2017;130(Supp1): 4325
Mato AR et al. Annals Onc 2017;28:1050-1056
Mato AR et al. Clin Cancer Res 2020;26:3589-3596
Lin VS et al. Blood 2020;135(25):2266-2270